INTRODUCTION: TaqIA polymorphism, a genetic variant associated with the expression level of dopamine D2 receptors in the brain, has been linked to various aspects of smoking behavior, including smoking prevalence, affective withdrawal symptoms, and smoking cessation outcome. However, its involvement in motivation to smoke cigarettes has not been elucidated. METHODS: The present study examined the possible differences in self-reported reasons to smoke and craving for smoking in 160 smokers participating in a clinical trial. RESULTS: Individuals with at least one A1 allele of the TaqIA polymorphism were more likely to report smoking for stimulating effects and to reduce negative affect compared with those lacking an A1 allele. The association of the A1 genotype with a higher probability and stronger motive to smoker to enhance cognitive functioning was evident in female but not in male smokers. Female A1 carriers also expected a greater likelihood of smoking for pleasure than those without an A1 allele. A1 subjects reported stronger craving for cigarettes during early days and the last phase of a 6-week abstinence period. DISCUSSION: These results support the idea that dopaminergic transmission plays an important role in the neurobiological basis of reasons for smoking and that the TaqIA variant is one of the genetic factors underlying individual differences in these aspects. These findings also have implications for improving treatment strategies to help individuals quit smoking by controlling their motivation to continue cigarette consumption.
INTRODUCTION: TaqIA polymorphism, a genetic variant associated with the expression level of dopamine D2 receptors in the brain, has been linked to various aspects of smoking behavior, including smoking prevalence, affective withdrawal symptoms, and smoking cessation outcome. However, its involvement in motivation to smoke cigarettes has not been elucidated. METHODS: The present study examined the possible differences in self-reported reasons to smoke and craving for smoking in 160 smokers participating in a clinical trial. RESULTS: Individuals with at least one A1 allele of the TaqIA polymorphism were more likely to report smoking for stimulating effects and to reduce negative affect compared with those lacking an A1 allele. The association of the A1 genotype with a higher probability and stronger motive to smoker to enhance cognitive functioning was evident in female but not in male smokers. Female A1 carriers also expected a greater likelihood of smoking for pleasure than those without an A1 allele. A1 subjects reported stronger craving for cigarettes during early days and the last phase of a 6-week abstinence period. DISCUSSION: These results support the idea that dopaminergic transmission plays an important role in the neurobiological basis of reasons for smoking and that the TaqIA variant is one of the genetic factors underlying individual differences in these aspects. These findings also have implications for improving treatment strategies to help individuals quit smoking by controlling their motivation to continue cigarette consumption.
Authors: Sean P David; Raymond Niaura; George D Papandonatos; William G Shadel; Gary J Burkholder; Dana M Britt; Amy Day; Jeffrey Stumpff; Kent Hutchison; Michael Murphy; Elaine Johnstone; Siân-Elin Griffiths; Robert T Walton Journal: Nicotine Tob Res Date: 2003-12 Impact factor: 4.244
Authors: Kenneth A Perkins; Caryn Lerman; Amy Grottenthaler; Melinda M Ciccocioppo; Melissa Milanak; Cynthia A Conklin; Andrew W Bergen; Neal L Benowitz Journal: Behav Pharmacol Date: 2008-09 Impact factor: 2.293
Authors: Anna V Wilkinson; Melissa L Bondy; Xifeng Wu; Jian Wang; Qiong Dong; Anthony M D'Amelio; Alexander V Prokhorov; Xia Pu; Robert K Yu; Carol J Etzel; Sanjay Shete; Margaret R Spitz Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-10-25 Impact factor: 4.254
Authors: Jason D Robinson; Francesco Versace; Cho Y Lam; Jennifer A Minnix; Jeffrey M Engelmann; Yong Cui; Maher Karam-Hage; Sanjay S Shete; Gail E Tomlinson; Tina T-L Chen; David W Wetter; Charles E Green; Paul M Cinciripini Journal: Front Psychiatry Date: 2013-09-23 Impact factor: 4.157